D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$708M |
| 2 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$614M |
| 3 |
Merck
MRK
|
+$521M |
| 4 |
Bank of America
BAC
|
+$492M |
| 5 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$285M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$646M |
| 2 |
Tesla
TSLA
|
+$607M |
| 3 |
Microsoft
MSFT
|
+$491M |
| 4 |
Accenture
ACN
|
+$482M |
| 5 |
Broadcom
AVGO
|
+$438M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.84% |
| 2 | Consumer Discretionary | 9.28% |
| 3 | Healthcare | 6.84% |
| 4 | Financials | 6.63% |
| 5 | Industrials | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
PUT
TKO Group
TKO
$13.7B
| $10.4M | 0.01% |
84,000
| – | – |
|
1302
Anterix
ATEX
$1.77B
| $10.4M | 0.01% |
275,856
+197,970
| +254% | +$7.63M |
|
|
YMAB
1303
DELISTED
Y-mAbs Therapeutics
YMAB
| $10.4M | 0.01% |
787,536
-138,921
| -15% | -$1.76M |
|
|
USAR
1304
USA Rare Earth Inc
USAR
$3.58B
| $10.4M | 0.01% |
963,823
+200,000
| +26% | +$2.13M |
|
1305
CALL
Nutanix
NTNX
$15.5B
| $10.3M | 0.01% |
174,400
+8,800
| +5% | +$483K |
|
1306
Collegium Pharmaceutical
COLL
$1.16B
| $10.3M | 0.01% |
265,602
+66,739
| +34% | +$2.38M |
|
1307
Upbound Group
UPBD
$1.22B
| $10.2M | 0.01% |
319,830
+185,915
| +139% | +$5.98M |
|
|
NVO
1308
PUT
Novo Nordisk
NVO
$220B
| $10.2M | 0.01% |
85,800
+72,800
| +560% | +$9.71M |
|
1309
Ventas
VTR
$48.7B
| $10.2M | 0.01% |
159,132
+80,195
| +102% | +$4.68M |
|
1310
CALL
Li Auto
LI
$13.1B
| $10.2M | 0.01% |
397,800
+49,900
| +14% | +$1.01M |
|
1311
CALL
Whirlpool
WHR
$2.47B
| $10.2M | 0.01% |
95,300
+18,800
| +25% | +$1.89M |
|
1312
NovoCure
NVCR
$2B
| $10.2M | 0.01% |
650,314
-48,980
| -7% | -$888K |
|
1313
PUT
Lamb Weston
LW
$7.29B
| $10.2M | 0.01% |
156,800
+140,700
| +874% | +$9.29M |
|
1314
CALL
Gilead Sciences
GILD
$163B
| $10.1M | 0.01% |
+120,600
| New | +$9.2M |
|
|
GPGI
1315
GPGI Inc
GPGI
$4.13B
| $10.1M | 0.01% |
867,205
+656,404
| +311% | +$5.56M |
|
1316
Century Communities
CCS
$2.04B
| $10.1M | 0.01% |
97,652
-15,792
| -14% | -$1.51M |
|
1317
Gogo Inc
GOGO
$546M
| $10.1M | 0.01% |
1,400,071
-337,414
| -19% | -$2.75M |
|
1318
PUT
Pultegroup
PHM
$24.7B
| $10M | 0.01% |
70,000
| – | – |
|
1319
Unilever
UL
$133B
| $10M | 0.01% |
+137,397
| New | +$9.5M |
|
|
RVNC
1320
DELISTED
Revance Therapeutics, Inc.
RVNC
| $10M | 0.01% |
1,932,205
+1,824,225
| +1,689% | +$9.07M |
|
1321
Canadian Imperial Bank of Commerce
CM
$107B
| $10M | 0.01% |
163,112
+106,312
| +187% | +$5.76M |
|
1322
Pitney Bowes
PBI
$2.46B
| $10M | 0.01% |
1,402,750
-224,884
| -14% | -$1.52M |
|
1323
CALL
Etsy
ETSY
$7.9B
| $9.98M | 0.01% |
179,700
+102,500
| +133% | +$5.82M |
|
1324
StoneCo
STNE
$2.65B
| $9.96M | 0.01% |
884,241
-888,101
| -50% | -$11.3M |
|
|
MPT
1325
CALL
Medical Properties Trust
MPT
$2.92B
| $9.96M | 0.01% |
1,701,800
+1,164,100
| +216% | +$5.74M |
|
Similar funds
D.E. Shaw & Co's Q3 2024 Portfolio in Review
As of Q3 2024, D.E. Shaw & Co held 5,052 positions worth $116B, up 8.9% from $107B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
D.E. Shaw & Co's Q3 2024 filing shows 599 new, 1,568 increased, 1,742 reduced and 558 closed positions. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 1,429,800 shares worth $115M. The largest sale was Adobe, an estimated $646M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- D.E. Shaw & Co's largest Q3 2024 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 1,429,800 shares worth $115M.
- D.E. Shaw & Co added most to NVIDIA in Q3 2024, an estimated $708M increase.
- D.E. Shaw & Co's biggest Q3 2024 reduction was Adobe, cutting an estimated $646M.
- D.E. Shaw & Co fully exited WestRock Company in Q3 2024, selling an estimated $148M.
- D.E. Shaw & Co's ten largest holdings make up 9.6% of its $116B portfolio in Q3 2024.
- D.E. Shaw & Co opened 599 new positions and closed 558 in Q3 2024.
- D.E. Shaw & Co's portfolio value rose 8.9% quarter-over-quarter to $116B.
Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.